Pre-made Pabinafusp benchmark antibody ( Whole mAb Fusion, anti-TFRC therapeutic antibody, Anti-CD71/IMD46/T9/TFR/TFR1/TR/TRFR/p90 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Pabinafusp biosimilar, Whole mAb Fusion, Anti-TFRC Antibody: Anti-CD71/IMD46/T9/TFR/TFR1/TR/TRFR/p90 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-420-1mg	1mg	Inquiry
GMP-Bios-ab-420-10mg	10mg	Inquiry
GMP-Bios-ab-420-100mg	100mg	Inquiry
GMP-Bios-ab-420-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Pabinafusp biosimilar, Whole mAb Fusion, Anti-TFRC Antibody: Anti-CD71/IMD46/T9/TFR/TFR1/TR/TRFR/p90 therapeutic antibody
INN Name	Pabinafusp
Target	TFRC
Format	Whole mAb Fusion
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2018
Year Recommended	2019
Companies	JCR Pharmaceuticals
Conditions Approved	Mucopolysaccharidosis II
Conditions Active	na
Conditions Discontinued	na
Development Tech	na